Urgent.ly Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Urgent.ly Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.19M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $142.91M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $184.65M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $187.59M | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $148.51M | Mar 29, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.19M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $142.91M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $184.65M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $187.59M | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $148.51M | Mar 29, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.78M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $31.56M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $37.88M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $20.15M | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $8.41M | Mar 29, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.43M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($44.03M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $74.73M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($95.98M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | ($56.34M) | Mar 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.87M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($27.19M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($46.10M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($53.55M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | ($49.76M) | Mar 29, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.21M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $13.93M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $16.91M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $16.73M | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $12.25M | Mar 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.36M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($30.79M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($65.15M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($54.24M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | ($57.21M) | Mar 29, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.65M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $54.07M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $121.19M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $46.94M | Mar 29, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.10M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $85.74M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $111.59M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $181.78M | Mar 29, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($46.45M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($31.67M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $9.60M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | ($181.17M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | ($120.57M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2020 | ($71.32M) | Mar 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($219.22M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($198.80M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($154.77M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($229.50M) | Mar 29, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.16M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $14.05M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $37.70M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $6.36M | Mar 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (39) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 26 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (949) | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | (1,061) | Mar 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (39) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 25 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (949) | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | (1,061) | Mar 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.19M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 1.12M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 13.31M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 154,786 | Mar 29, 2024 |